According to a release issued to the BSE, the product will be developed and manufactured by Strides exclusively for STADA's sale in the USA.
Currently, Strides has twelve manufacturing plants worldwide and its Indian plant will be going for USFDA inspection shortly, the release added.
Arun Kumar, Managing Director and Group CEO to Strides stated, "The Strides STADA relationship is reflection of the Strides partnership philosophy. Strides intends to become a niche provider of quality generics for the US market."
